{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:54:49Z","timestamp":1772117689701,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd006829","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,9,12]],"date-time":"2012-09-12T00:00:00Z","timestamp":1347408000000}}],"reference-count":144,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006829.pub2","type":"journal-article","created":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T18:33:11Z","timestamp":1346783591000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Combined corticosteroid and long-acting beta\n                    <sub>2<\/sub>\n                    -agonist in one inhaler versus long-acting beta\n                    <sub>2<\/sub>\n                    -agonists for chronic obstructive pulmonary disease"],"prefix":"10.1002","volume":"2013","author":[{"given":"Luis Javier","family":"Nannini","sequence":"first","affiliation":[{"name":"Hospital E Peron; Pulmonary Section; Ruta 11 Y Jm Estrada G. Baigorria Santa Fe - Rosario Argentina 2152"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toby J","family":"Lasserson","sequence":"additional","affiliation":[{"name":"The Cochrane Collaboration; Cochrane Editorial Unit; 11-13 Cavendish Square London UK W1G 0AN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillippa","family":"Poole","sequence":"additional","affiliation":[{"name":"University of Auckland; Department of Medicine; Private Bag 92019 Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,9,12]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD006829.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/15412550903140881","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50) on COPD exacerbations and impact on patient outcomes","volume":"6","author":"Anzueto","year":"2009","journal-title":"Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0002|cit2","unstructured":"Borgstrom L Asking L Olsson H Peterson S Lack of interaction between disease severity and therapeutic response with budesonide\/formoterol in a single inhaler [Abstract] American Thoracic Society 100th International Conference, May 21-26 2004 C22 [Poster 505]"},{"issue":"6","key":"10.1002\/14651858.CD006829.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0004|cit4","first-page":"P436","article-title":"Budesonide\/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]","volume":"22 Suppl 45","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0005|cit5","first-page":"P1587","article-title":"COPD exacerbations are reduced by budesonide\/formoterol in a single inhaler [Abstract]","volume":"22 Suppl 45","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0006|cit6","unstructured":"Calverley PMA Olsson H Symbicort International COPD Study Group Budesonide\/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract] American Thoracic Society 99th International Conference 2003 B024 [Poster 418]"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0007|cit7","unstructured":"Calverley PMA Peterson S Combining budesonide\/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract] American Thoracic Society 99th International Conference 2003 D092 [Poster 211]"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0008|cit8","unstructured":"Calverley PMA St\u00e5hl E Jones PW Budesonide\/formoterol improves the general health status of patients with COPD [Abstract] American Thoracic Society 2005 International Conference; May 20-25; San Diego, California 2005 B93 [Poster 303]"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0009|cit9","first-page":"Poster 1917","article-title":"Budesonide\/formoterol is a well-tolerated long term maintenance therapy for COPD","volume":"26 Suppl 49","author":"Calverley","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0010|cit10","first-page":"P435","article-title":"Budesonide\/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]","volume":"22 Suppl 45","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0011|cit11","unstructured":"Halpin D Stahl E Lundback B Anderson F Peterson S Treatment costs and number needed to treat (NNT) with budesonide\/formoterol to avoid one exacerbation of COPD [Abstract] American Thoracic Society 100th International Conference, May 21-26 2004 D22 [Poster 525]"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0012|cit12","unstructured":"Halpin DMG Larsson T Calverley PMA How many patients with COPD must be treated with budesonide\/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract] American Thoracic Society 2005 International Conference; May 20-25; San Diego, California 2005 B93 [Poster 314]"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0015|cit13","unstructured":"Jones PW Stahl E Budesonide\/formoterol in a single inhaler improves health status in patients with COPD [abstract] American Thoracic Society 99th International Conference 2003 B024 [Poster 419]"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0013|cit14","first-page":"Abstract 1352","article-title":"Budesonide \/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]","volume":"26 Suppl 49","author":"Jones","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0014|cit15","unstructured":"Jones PW St\u00e5hl E Reducing exacerbations leads to a better health-related quality of life in patients with COPD 13th ERS Annual Congress, 27th September, 2003, Vienna 2003 P1586"},{"issue":"88","key":"10.1002\/14651858.CD006829.pub2-BIB0018|cit16","first-page":"14","article-title":"Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide\/formoterol","volume":"13","author":"Lofdahl","year":"2004","journal-title":"European Respiratory Review"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0016|cit17","first-page":"P433","article-title":"Budesonide\/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]","volume":"22 Suppl 45","author":"Lofdahl","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD006829.pub2-BIB0017|cit18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00019053-200523040-00006","article-title":"Cost effectiveness of budesonide\/formoterol in a single inhaler for COPD compared with each monocomponent used alone","volume":"23","author":"Lofdahl","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0019|cit19","unstructured":"Dal Negro R Micheletto C Trevsian F Tognella S [A98] Salmeterol and fluticasone 50ug\/250ug BiD versus salmeterol 50ug bid and versus placebo in the long term treatment of COPD Proceedings of the 98th International American Thoracic Society Conference 2002 http:\/\/www.abstracts on-line.com\/abstracts\/ATS"},{"issue":"4","key":"10.1002\/14651858.CD006829.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1094-5539(03)00065-8","article-title":"Salmeterol & fluticasone 50 microg\/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline","volume":"16","author":"Dal Negro","year":"2003","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.rmed.2008.04.019","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50 microg) or salmeterol (50 microg) on COPD exacerbations","volume":"102","author":"Ferguson","year":"2008","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0022|cit22","unstructured":"SCO40043 A randomized, double-blind, parallel-group, 52-week study to compare the effect of fluticasone propionate\/salmeterol DISKUS\u00ae 250\/50mcg bid with salmeterol DISKUS\u00ae 50mcg bid on the annual rate of moderate\/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD) http:\/\/ctr.gsk.co.uk (accessed 8th April 2008)"},{"issue":"3","key":"10.1002\/14651858.CD006829.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1378\/chest.124.3.834","article-title":"The efficacy and safety of fluticasone propionate (250 micro g)\/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD","volume":"124","author":"Hanania","year":"2003","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD006829.pub2-BIB0024|cit24","first-page":"A279","article-title":"Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus","volume":"163 Suppl","author":"Hanania","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0025|cit25","first-page":"P434","article-title":"Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg\/fluticasone propionate 250mcg combination [Abstract]","volume":"22 Suppl 45","author":"Horstman","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0026|cit26","unstructured":"Mahler DA Darken P Brown CP Knobil K Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract] National COPD Conference; Arlington, Virginia 2003 Abstract 1081"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0027|cit27","first-page":"P429","article-title":"Predicting lung function responses to salmeterol\/fluticasone propionate combination therapy in COPD [Abstract]","volume":"22 Suppl 45","author":"Mahler","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0028|cit28","unstructured":"SFCA3007 A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 250mcg BID individually and in combination as Salmeterol 50mcg\/Fluticasone Propionate 250mcg BID (SFC 50\/250) compared to placebo in COPD subjects GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk) 2005"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0029|cit29","first-page":"51s","article-title":"Patients with COPD using salmeterol\/fluticasone propionate combination therapy experience improved quality of life","volume":"22 Suppl 45","author":"Spencer","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0030|cit30","first-page":"290s","article-title":"The clinical significance of treatment benefits with the salmeterol\/fluticasone propionate 50\/500mcg combination in COPD","volume":"24 Suppl 48","author":"Spencer","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0032|cit31","first-page":"Abstract 1944","article-title":"Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD","volume":"26 Suppl 49","author":"Kardos","year":"2005","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD006829.pub2-BIB0031|cit32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1164\/rccm.200602-244OC","article-title":"Impact of salmeterol\/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease","volume":"175","author":"Kardos","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0033|cit33","unstructured":"SCO30006 A randomised, double-blind, parallel-group study to investigate the protective effect of the combination of fluticasone and salmeterol (500\/50\u00b5g bid via the DISKUS) compared with salmeterol (50\u00b5g bid via the DISKUS) on the incidence of moderate to severe exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) (GOLD III\/IV) GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk) 2005"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0034|cit34","unstructured":"Vogelmeier C Combination therapy with salmeterol and fluticasone propionate (SFC) improves quality of life (QoL) more than salmeterol (SAL) alone in COPD 42nd Nordic Lung Conference Trondheim 2005"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0035|cit35","unstructured":"Vogelmeier CF Wencker M Glaab TH Kardos P Number needed to treat (NNT) to reduce exacerbations in severe COPD comparing salmeterol\/fluticasone propionate (SFC) with salmeterol (SAL) treatment Proceedings of the American Thoracic Society 2006 A110"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0036|cit36","unstructured":"Mahler DA Darken P Brown CP Knobil K Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) http:\/\/www.abstracts2view.com 2003"},{"issue":"8","key":"10.1002\/14651858.CD006829.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.2112055","article-title":"Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease","volume":"166","author":"Mahler","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0038|cit38","unstructured":"SFCA3006 A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 500mcg BID individually and in combination as Salmeterol 50mcg\/Fluticasone Propionate 500mcg BID (SFC 50\/500) compared to placebo in COPD subjects GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk) 2005"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0039|cit39","first-page":"51s","article-title":"Patients with COPD using salmeterol\/fluticasone propionate combination therapy experience improved quality of life","volume":"22 Suppl 45","author":"Spencer","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0040|cit40","unstructured":"Spencer MD Anderson JA Salmeterol\/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract] American Thoracic Society 2005 International Conference; May 20-25; San Diego, California 2005 B93 [Poster 308]"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0041|cit41","first-page":"290s","article-title":"The clinical significance of treatment benefits with the salmeterol\/fluticasone propionate 50\/500mcg combination in COPD","volume":"24 Suppl 48","author":"Spencer","year":"2004","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD006829.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1378\/chest.130.3.647","article-title":"Effect of fluticasone propionate\/salmeterol on lung hyperinflation and exercise endurance in COPD","volume":"130","author":"O'Donnell","year":"2006","journal-title":"Chest"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0043|cit43","unstructured":"SCO40030 A randomized, double-blind, placebo-controlled, parallel group clinical trial evaluating the effect of the fluticasone propionate\/salmeterol combination product 250\/50mcg bid via DISKUS and salmeterol 50mcg bid via DISKUS on lung hyperinflation in subjects with chronic obstructive pulmonary disease (COPD) GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk) 2005"},{"issue":"5","key":"10.1002\/14651858.CD006829.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00003495-200969050-00004","article-title":"Efficacy and tolerability of budesonide\/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease. Results from a 1-year randomized controlled clinical trial","volume":"69","author":"Rennard","year":"2009","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0045|cit45","unstructured":"SCO100470 A multicentre, randomised, double-blind, parallel group, 24-week study to compare the effect of the salmeterol\/fluticasone propionate combination product 50\/250mcg, with salmeterol 50mcg both delivered twice daily via the DISKUS\/ACCUHALER inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD) GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk) 2006"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0046|cit46","first-page":"iii43","article-title":"Budesonide\/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]","volume":"57 Suppl III","author":"Anderson","year":"2002","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0047|cit47","unstructured":"Borgstrom L Asking L Olsson H Peterson S Lack of interaction between disease severity and therapeutic response with budesonide\/formoterol in a single inhaler [Abstract] American Thoracic Society 100th International Conference, May 21-26 2004 C22 [Poster 505]"},{"issue":"3","key":"10.1002\/14651858.CD006829.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1183\/09031936.05.00143404","article-title":"Relationship between respiratory symptoms and medical treatment in exacerbations of COPD","volume":"26","author":"Calverley","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0051|cit49","unstructured":"Calverley PMA Effect of budesonide\/formoterol on severe exacerbations and lung function in moderate to severe COPD Thorax BTS Winter meeting 2002 S145"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0049|cit50","first-page":"Poster 1917","article-title":"Budesonide\/formoterol is a well-tolerated long term maintenance therapy for COPD","volume":"26 Suppl 49","author":"Calverley","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0050|cit51","first-page":"P435","article-title":"Budesonide\/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]","volume":"22 Suppl 45","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0052|cit52","unstructured":"Campbell LM Szafranski W Budesonide\/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD Thorax BTS Winter meeting 2002 S143"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0053|cit53","unstructured":"Campell LW Szafranski W Budesonide\/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate-severe COPD Thorax BTS Winter meeting 2002 S141"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0054|cit54","first-page":"242 [P1575]","article-title":"Budesonide\/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD","volume":"20 Suppl 38","author":"Dahl","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0055|cit55","first-page":"242 [P1574]","article-title":"Budesonide\/formoterol in a single inhaler provides sustained relief from symptoms and night-time awakenings in moderate-severe COPD: results from symptoms and night-time awakenings in moderate to severe COPD: results from a 1-year study","volume":"20 Suppl 38","author":"Egede","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0056|cit56","unstructured":"Halpin D Stahl E Lundback B Anderson F Peterson S Treatment costs and number needed to treat (NNT) with budesonide\/formoterol to avoid one exacerbation of COPD [Abstract] American Thoracic Society 100th International Conference, May 21-26 2004 D22 [Poster 525]"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0057|cit57","first-page":"250 [P1613]","article-title":"Improvement in health status in patients with moderate to severe COPD after treatment with budesonide\/formoterol in a single inhaler","volume":"20 Suppl 38","author":"Jones","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0058|cit58","first-page":"242 [P1577]","article-title":"Budesonide\/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1-year study of patients with moderate to severe COPD","volume":"20 Suppl 38","author":"Korsgaard","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0059|cit59","first-page":"242 [P1573]","article-title":"Budesonide\/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study","volume":"20 Suppl 38","author":"Lange","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"88","key":"10.1002\/14651858.CD006829.pub2-BIB0060|cit60","first-page":"14","article-title":"Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide\/formoterol","volume":"13","author":"Lofdahl","year":"2004","journal-title":"European Respiratory Review"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0061|cit61","first-page":"242 [P1576]","article-title":"Budesonide\/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD","volume":"20 Suppl 38","author":"Milanowski","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD006829.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"14","key":"10.1002\/14651858.CD006829.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2165\/00003495-200868140-00004","article-title":"Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease. Results of a 6-month randomized clinical trial","volume":"68","author":"Tashkin","year":"2008","journal-title":"Drugs"},{"issue":"8","key":"10.1002\/14651858.CD006829.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0065|cit65","first-page":"578s","article-title":"Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study","volume":"22 Suppl 45","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0066|cit66","first-page":"34s","article-title":"The TORCH (TOwards a Revolution in COPD Health) study: salmeterol\/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years","volume":"28 Suppl 50","author":"Celli","year":"2006","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0067|cit67","first-page":"34s","article-title":"The TORCH (TOwards a Revolution in COPD Health) study: salmeterol\/fluticasone propionate (SFC) improves survival in COPD over three years","volume":"28 Suppl 50","author":"Ferguson","year":"2006","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0068|cit68","unstructured":"Jenkins CR Calverley PMA Celli B Ferguson G Jones PW Pride N Seasonal Patterns of Exacerbation Rates in the TORCH Survival Study http:\/\/www.abstracts2view.com 2007 A839"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Jones PW Calverley P Celli B Ferguson G Jenkins C Pride N Trans-Regional Validity of the SGRQ in the TORCH Survival Study http:\/\/www.abstracts2view.com 2007 A122","DOI":"10.1378\/chest.130.4_MeetingAbstracts.122S-a"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/thx.2006.072348","article-title":"Ascertainment of cause-specific mortality in COPD : operations of the TORCH Clinical Endpoint Committee","volume":"62","author":"McGarvey","year":"2007","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0071|cit71","unstructured":"SCO30003 A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol\/fluticasone propionate (SERETIDE\u00ae\/VIANI\u00ae\/ADVAIR\u00ae) 50\/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS\u00ae\/ACCUHALER\u00ae inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment www.ctr.gsk.co.uk 2006"},{"issue":"2","key":"10.1002\/14651858.CD006829.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1183\/09031936.04.00120603","article-title":"The TORCH (TOwards a Revolution in COPD Health) survival study protocol","volume":"24","author":"Vestbo","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0073|cit73","unstructured":"Wise RA McGarvey LP John M Anderson JA Zvarich MT Reliability of cause-specific mortality adjudication in a COPD clinical trial http:\/\/www.abstracts2view.com 2007 A120"},{"issue":"9356","key":"10.1002\/14651858.CD006829.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0075|cit75","unstructured":"Calverley PMA Pauwels RA Vestbo J Jones PW Pride NB Gulsvik A Clinical improvements with salmeterol \/ fluticasone propionate combination in differing severities of COPD http:\/\/www.abstracts2view.com 2003 A035 [Poster D50]"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0076|cit76","unstructured":"Calverley PMA Pauwels RA Vestbo J Jones PW Pride NB Gulsvik A Salmeterol\/fluticasone propionate combination for one year provides greater clinical benefit than its individual components Proceedings of the 98th International American Thoracic Society Conference http:\/\/www.abstracts-on-line.com\/abstracts\/ATS 2002 A98 [Poster 306]"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0077|cit77","first-page":"242 [P1572]","article-title":"Safety of salmeterol\/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease","volume":"20 Suppl 38","author":"Calverly","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0078|cit78","unstructured":"Hunjan MK Chandler F Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol\/fluticasone propionate combination (SFC) and associated costs [Abstract] American Thoracic Society 100th International Conference, May 21-26 2004 D22 [Poster 503]"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0079|cit79","first-page":"291s","article-title":"Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol\/ fluticasone propionate combination (seretide) and salmeterol","volume":"24 Suppl 48","author":"Hunjan","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0080|cit80","first-page":"513s","article-title":"Salmeterol\/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate\/severe COPD","volume":"24 Suppl 48","author":"Hunjan","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0081|cit81","unstructured":"Jones PW Edin HM Anderson J Salmeterol\/fluticasone propionate combination improves health status in COPD patients Proceedings of the 98th International American Thoracic Society Conference http:\/\/www.abstracts-on-line.com\/abstracts\/ATS 2002 A39 [Poster K39]"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0082|cit82","first-page":"Abstract 1352","article-title":"Budesonide \/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]","volume":"26 Suppl 49","author":"Jones","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0083|cit83","unstructured":"Jones PW Vestbo J Pauwels RA Calverley PMA Anderson JA Spencer MD Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study 13th ERS Annual Congress, 27 Spetember 2003, Vienna 2003 P1593"},{"issue":"6","key":"10.1002\/14651858.CD006829.pub2-BIB0084|cit84","first-page":"727","article-title":"Inhalational combination therapy in chronic obstructive lung disease. Tristan study","volume":"45","author":"Nitschmann","year":"2004","journal-title":"German Internist"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0085|cit85","unstructured":"Pauwels R Vestbo J Calverley PMA Jones PW Pride NB Gulsvik A Characterization of exacerbations in the TRISTAN study of salmeterol\/fluticasone propionate (SFC) combination in moderate to severe COPD http:\/\/www.abstracts2view.com 2003"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0086|cit86","first-page":"240 [P1569]","article-title":"Reduction of exacerbations with salmeterol\/fluticasone combination 50\/500 mcg bd in the treatment of chronic obstructive pulmonary disease","volume":"20 Suppl 38","author":"Pauwels","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0087|cit87","unstructured":"SFCB3024 A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of the salmeterol\/FP combination product at a strength of 50\/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS\u2122\/ACCUHALER\u2122, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk) 2005"},{"issue":"6","key":"10.1002\/14651858.CD006829.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2165\/00019053-200523060-00008","article-title":"Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease","volume":"23","author":"Spencer","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0089|cit89","first-page":"290s","article-title":"The clinical significance of treatment benefits with the salmeterol\/fluticasone propionate 50\/500mcg combination in COPD","volume":"24 Suppl 48","author":"Spencer","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0090|cit90","first-page":"240 [P1570]","article-title":"Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease","volume":"20 Suppl 38","author":"Vestbo","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD006829.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1136\/thx.2004.025411","article-title":"Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease","volume":"60","author":"Vestbo","year":"2005","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0092|cit92","unstructured":"Vestbo J Pauwels RS Calverley PMA Jones PW Pride NB Gulsvik A Salmeterol \/ fluticasone propionate combination produces improvement in lung function detectable within 24 Hours in moderate to severe COPD http:\/\/www.abstracts2view.com 2003"},{"issue":"11","key":"10.1002\/14651858.CD006829.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.rmed.2004.03.017","article-title":"Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD","volume":"98","author":"Vestbo","year":"2004","journal-title":"Respiratory Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006829.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006829.pub2-BIB0095|cit95","first-page":"258","article-title":"Effects of tiotropium combined with either salmeterol or salmeterol\/fluticasone in moderate to severe COPD","volume":"16","author":"Kaplan","year":"2007","journal-title":"Primary Care Respiratory Journal"},{"issue":"11","key":"10.1002\/14651858.CD006829.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1136\/thx.2006.071068","article-title":"Effect of salmeterol\/fluticasone propionate on airway inflammation in COPD: A randomised controlled trial","volume":"62","author":"Bourbeau","year":"2007","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD006829.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.rmed.2006.08.013","article-title":"The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD","volume":"101","author":"Cukier","year":"2007","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0098|cit98","first-page":"33s","article-title":"Effects of tiotropium and salmeterol\/fluticasone combination on lung hyperinflation dyspnea and exercise tolerance in COPD [Abstract].","volume":"28 Suppl 50","author":"Golabi","year":"2006","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0099|cit99","unstructured":"Haque RA Torrego A Essilfie-Quaye S Kharitonov SA Johnson M Adcock IM Effect of salmeterol and fluticasone on glucocorticoid receptor translocation in sputum macrophages and peripheral blood mononuclear cells from patients with chronic obstructive pulmonary disease Proceedings of the American Thoracic Society 2006 A848"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0100|cit100","unstructured":"GlaxoSmithKline (SCO40036) Multicentre, randomised, double-blind, double-dummy, parallel group, 104-week study to compare the effect of the salmeterol\/fluticasone propionate combination product (SERETIDE*) 50\/500mcg delivered twice daily via the DISKUS*\/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the HandiHaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD) http:\/\/ctr.gsk.co.uk (accessed 8th April 2008)"},{"issue":"3","key":"10.1002\/14651858.CD006829.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/15412550701407862","article-title":"Investigating new standards for prophylaxis in reduction of exacerbations - The INSPIRE study methodology","volume":"4","author":"Seemungal","year":"2007","journal-title":"Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0102|cit102","first-page":"A112","article-title":"The INSPIRE study: effect of salmeterol\/fluticasone propionate versus tiotropium bromide on COPD exacerbations","volume":"12 Suppl 4","author":"Wedzicha","year":"2007","journal-title":"Respirology"},{"issue":"5","key":"10.1002\/14651858.CD006829.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1440-1843.2007.01132.x","article-title":"Fast onset of effect of budesonide\/formoterol versus salmeterol\/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction","volume":"12","author":"Lindberg","year":"2007","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0104|cit104","first-page":"214s","article-title":"Budesonide\/formoterol (B\/F) has an onset of action that is similar to salbutamol and faster than salmeterol\/fluticasone in patients with COPD","volume":"28 Suppl 50","author":"Lindberg","year":"2006","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD006829.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/fampra\/cml076","article-title":"Lower inhaled steroid requirement with a fluticasone\/salmeterol combination in family practice patients with asthma or COPD","volume":"24","author":"Schermer","year":"2007","journal-title":"Family Practice"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0106|cit106","unstructured":"Sethi S Grove L Wrona C Maloney J Prevalence of bacterial colonization in COPD is not altered by fluticasone\/salmeterol Proceedings of the American Thoracic Society 2006 A115"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0107|cit107","first-page":"662s","article-title":"Modulation of sputum gene expression in COPD by fluticasone \/salmeterol","volume":"28 Suppl 50","author":"Sutherland","year":"2006","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0108|cit108","first-page":"30s","article-title":"The efficacy of salmeterol\/fluticasone (SF) for 6 month's therapy at severe COPD patients","volume":"28 Suppl 50","author":"Trofimenko","year":"2006","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD006829.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"182s","DOI":"10.1378\/chest.130.4_MeetingAbstracts.182S-a","article-title":"The efficacy and safety of fluticasone propionate 500 mg\/salmeterol 50 mg combined via diskus\/accuhaler in Chinese patients with chronic obstructive pulmonary disease (COPD)","volume":"130","author":"Zheng","year":"2006","journal-title":"Chest"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0110|cit110","first-page":"A150","article-title":"The efficacy and safety of salmeterol 50\u00b5g\/fluticasone propionate 500\u00b5g combined via accuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]","volume":"11 Suppl 5","author":"Zhong","year":"2006","journal-title":"Respirology"},{"issue":"3","key":"10.1002\/14651858.CD006829.pub2-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001104","article-title":"Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease","author":"Appleton","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD006829.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1183\/09031936.05.00143404","article-title":"Relationship between respiratory symptoms and medical treatment in exacerbations of COPD","volume":"26","author":"Calverley","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD006829.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1164\/rccm.200712-1869OC","article-title":"Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study","volume":"178","author":"Celli","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006829.pub2-BIB0116|cit116","first-page":"778\u201384","article-title":"Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease","volume":"164","author":"Dahl","year":"2001","journal-title":"American Journal of Resiratory Critical Care Medicine"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0117|cit117","unstructured":"Global Strategy for Diagnosis Management Prevention of COPD Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease http:\/\/www.goldcopd.org 2010"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0118|cit118","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St George\u2019s Respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD: Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"2","key":"10.1002\/14651858.CD006829.pub2-BIB0120|cit120","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008989","article-title":"Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease","author":"Karner","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD006829.pub2-BIB0121|cit121","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009039.pub2","article-title":"The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease","author":"Karner","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006829.pub2-BIB0122|cit122","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008532.pub2","article-title":"Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease","author":"Karner","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD006829.pub2-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009285.pub2","article-title":"Tiotropium versus placebo for chronic obstructive pulmonary disease","author":"Karner","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0954-6111(03)80016-1","article-title":"Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale","volume":"97 Suppl A","author":"Leidy","year":"2003","journal-title":"Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006829.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1378\/chest.115.4.957","article-title":"Efficacy of salmeterol xinafoate in the treatment of COPD","volume":"115","author":"Mahler","year":"1999","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD006829.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/thx.2003.008730","article-title":"Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study","volume":"59","author":"Miravitlles","year":"2004","journal-title":"Thorax"},{"issue":"3","key":"10.1002\/14651858.CD006829.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.rmed.2006.07.010","article-title":"Patient's perception of exacerbations of COPD - the PERCEIVE study","volume":"101","author":"Miravitlles","year":"2007","journal-title":"Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006829.pub2-BIB0128|cit128","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006826","article-title":"Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease","author":"Nannini","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006829.pub2-BIB0129|cit129","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006826","article-title":"Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease","author":"Nannini","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0130|cit130","first-page":"1","article-title":"Managament of chronic obstructive pulmonary disease in primary and secondary care","volume":"available at ht","author":"National Collaborating Centre for Chronic Conditions","year":"2010","journal-title":"http:\/\/www.nice.org.uk"},{"issue":"1","key":"10.1002\/14651858.CD006829.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/thx.52.1.67","article-title":"Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease","volume":"52","author":"Osman","year":"1997","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0132|cit132","unstructured":"Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration Review Manager (RevMan) Version 5.1 2008"},{"issue":"5","key":"10.1002\/14651858.CD006829.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"398s","DOI":"10.1378\/chest.117.5_suppl_2.398S","article-title":"Toward a consensus definition of for COPD exacerbations","volume":"117","author":"Rodriguez-Roisin","year":"2000","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD006829.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/archinternmed.2008.550","article-title":"Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis","volume":"169","author":"Singh","year":"2009","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/COPD.S6942","article-title":"An overview of the benefits and draw backs of inhaled corticosteroids in chronic obstructive pulmonary disease","volume":"5","author":"Singh","year":"2010","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"12","key":"10.1002\/14651858.CD006829.pub2-BIB0136|cit136","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007033.pub3","article-title":"Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease","author":"Spencer","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD006829.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1164\/rccm.200508-1338PP","article-title":"Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease","volume":"173","author":"Suissa","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/thorax.58.11.937","article-title":"Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis","volume":"58","author":"Sutherland","year":"2003","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD006829.pub2-BIB0139|cit139","unstructured":"Cates CJ Visual Rx 2.0 2003"},{"issue":"7","key":"10.1002\/14651858.CD006829.pub2-BIB0140|cit140","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007891.pub2","article-title":"Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease","author":"Welsh","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006829.pub2-BIB0141|cit141","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002991","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease","author":"Yang","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006829.pub2-BIB0142|cit142","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003794","article-title":"Combined corticosteroid and longacting bronchodilator in one inhaler for chronic obstructive pulmonary disease","author":"Nannini","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006829.pub2-BIB0143|cit143","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003794.pub2","article-title":"Combined corticosteroid and long-acting beta-agonist in one inhaler for chronic obstructive pulmonary disease","author":"Nannini","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD006829.pub2-BIB0144|cit144","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006829","article-title":"Combined corticosteroid and long-acting beta-agonist in one inhaler for chronic obstructive pulmonary disease","author":"Nannini","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006829.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T09:32:19Z","timestamp":1727170339000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006829.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,9,12]]},"references-count":144,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006829.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717958451.793466071","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,12]]}}}